跳至主要内容
临床试验/IRCT201112201859N3
IRCT201112201859N3已完成3 期

The Comparison of safety and Efficacy of ReciGen and Rebif in patients with Relapsing Multiple Sclerosis

Cinnagen Pharmaceutical0 个研究点目标入组 54 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
54

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 50 years(—)
性别
All

入选标准

  • Inclusion Criteria:
  • 1.Relapsing-Remitting MS patients based on McDonald's Criteria
  • 2.ages between 18-50
  • 3.EDSS=<5.5
  • 4.Signing informed consent form
  • -Inclusion Criteria:
  • 1.Pregnancy during trial or intention to get pregnant in start of trial
  • 2.Psychiatric disease or major depression
  • 3.Past history of Suicide
  • 4.Allergy/hypersensitivity reaction to medication
  • 5.IVIG treatment within 6 months prior to trial
  • 6.Plasma Exchange within 6 months prior to trial
  • 7.Cytotoxic Medication use during study
  • 8.Impaired Liver Function Tests (3times Nl range)
  • 9.Leukopenia (less than half the Nl range)
  • 10.failure to follow-up for more than 4 weeks (with recording the reason)

排除标准

  • 未提供

研究者

发起方
Cinnagen Pharmaceutical

相似试验